AMGEN INC. $750,000,000 1.850% SENIOR NOTES DUE 2021 $750,000,000 2.250% SENIOR NOTES DUE 2023 $1,250,000,000 2.600% SENIOR NOTES DUE 2026 $1,000,000,000 4.400% SENIOR NOTES DUE 2045Underwriting Agreement • August 19th, 2016 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 1.850% Senior Notes due 2021 (the “2021 Notes”), $750,000,000 principal amount of its 2.250% Senior Notes due 2023 (the “2023 Notes”), $1,250,000,000 principal amount of its 2.600% Senior Notes due 2026 (the “2026 Notes”) and $1,000,000,000 principal amount of its 4.400% Senior Notes due 2045 (the “2045 Notes”), and together with the 2021 Notes, 2023 Notes and the 2026 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). Goldman, Sachs & Co., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and HSBC Securities (USA) Inc. have agreed to act as representatives of
